| Literature DB >> 32728133 |
Renin Toms1,2, Darren J Mayne3,4,5,6, Xiaoqi Feng4,7,8, Andrew Bonney3,4.
Abstract
Cardiometabolic risk factors (CMRFs) demonstrate significant geographic variation in their distribution. The study aims to quantify the general contextual effect of the areas on CMRFs; and the geographic variation explained by area-level socioeconomic disadvantage. A cross sectional design and multilevel logistic regression methods were adopted. Data included objectively measured routine pathology test data between years 2012 and 2017 on: fasting blood sugar level; glycated haemoglobin; total cholesterol; high density lipoprotein; urinary albumin creatinine ratio; estimated glomerular filtration rate; and body mass index. The 2011 Australian census based Index of Relative Socioeconomic Disadvantage (IRSD) were the area-level study variables, analysed at its smallest geographic unit of reporting. A total of 1,132,029 CMRF test results from 256,525 individuals were analysed. After adjusting for individual-level covariates, all CMRFs significantly associated with IRSD and the probability of higher risk CMRFs increases with greater area-level disadvantage. Though the specific contribution of IRSD in the geographic variation of CMRF ranged between 57.8 and 14.71%, the general contextual effect of areas were found minimal (ICCs 0.6-3.4%). The results support universal interventions proportional to the need and disadvantage level of populations for the prevention and control of CMRFs, rather than any area specific interventions as the contextual effects were found minimal in the study region.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32728133 PMCID: PMC7391748 DOI: 10.1038/s41598-020-69552-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Definitions of higher risk CMRFs test results.
| Definition | ||
|---|---|---|
| 1 | High FBSL | FBSL ≥ 7.0 mmol/L[ |
| 2 | High HbA1c | HbA1c > 7.5% [ |
| 3 | High TC | TC ≥ 5.5 mmol/L [ |
| 4 | Low HDL | HDL < 1 mmol/L [ |
| 5 | High ACR | ACR ≥ 30 mcg/L to mg/L [ |
| 6 | Low eGFR | eGFR < 60 mL/min/1.73 m2
[ |
| 7 | Obesity | BMI ≥ 30 kg/m2
[ |
CMRFs Cardiometabolic risk factors, FBSL Fasting Blood Sugar Level, HbA1c Glycated Haemoglobin, TC Total Cholesterol, HDL High Density Lipoprotein, ACR Albumin Creatinine Ratio, eGFR estimated Glomerular Filtration Rate, BMI Body Mass Index.
Figure 1Flow chart of the included/excluded tests in the CMRFs test data.
Table of excluded test data which had missing details.
| FBSL | HbA1c | TC | HDL | ACR | eGFR | BMI | Total | |
|---|---|---|---|---|---|---|---|---|
| Extracted | 193,680 | 73,885 | 194,816 | 182,237 | 50,790 | 244,166 | 192,455 | 1,132,029 |
| Test value | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Age | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 7 |
| Sex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IRSD | 182 | 78 | 191 | 174 | 53 | 256 | 193 | 1,154 |
| Excluded tests | 184 | 79 | 192 | 175 | 53 | 258 | 194 | 1,162 |
| Total n | 193,496 | 73,806 | 194,624 | 182,062 | 50,737 | 243,908 | 192,261 | 1,130,894 |
| (%) | (17.11) | (6.53) | (17.21) | (16.10) | (4.49) | (21.57 | (17.00) | (100.00) |
FBSL Fasting Blood Sugar Level, HbA1c Glycated Haemoglobin, TC Total Cholesterol, HDL High Density Lipoprotein, ACR Albumin Creatinine Ratio, eGFR estimated Glomerular Filtration Rate, BMI Body Mass Index, IRSD Index of the Relative Socioeconomic Disadvantage, SA1 Statistical Area level 1.
Cross-tabulation of individual CMRFs (FBSL, HbA1c, TC and HDL) with the variables in study.
| CMRFs | FBSL | HbA1c | TC | HDL | ||||
|---|---|---|---|---|---|---|---|---|
| Total tests | Total tests | Total tests | Total tests | |||||
| Rates | 193,496 | 16,259 (8.4) | 73,806 | 7,920 (10.73) | 194,624 | 57,506 (29.55) | 182,062 | 21,238 (11.67) |
| Male | 83,603 | 9,279 (4.8) | 35,757 | 4,444 (6.02) | 90,950 | 23,503 (12.0) | 85,266 | 15,872 (8.72) |
| Female | 109,893 | 6,980 (3.6) | 38,049 | 3,476 (4.71) | 103,674 | 34,003 (17.47) | 96,796 | 5,366 (2.95) |
| 18–29 | 19,747 | 238 (0.1) | 3,480 | 250 ( 0.34) | 14,247 | 2,127 (1.09) | 11,435 | 1,377 (0.76) |
| 30–39 | 23,515 | 459 (0.2) | 4,889 | 293 ( 0.40) | 18,960 | 4,889 (2.51) | 16,787 | 2,301 (1.26) |
| 40–49 | 29,424 | 1,265 (0.65) | 8,447 | 760 ( 1.03) | 31,395 | 10,719 (5.51) | 29,339 | 3,585 (1.97) |
| 50–59 | 37,085 | 2,948 (1.52) | 13,510 | 1,507 (2.04) | 39,663 | 16,316 (8.38) | 37,824 | 4,283 (2.35) |
| 60–69 | 37,962 | 4,670 (2.41) | 17,665 | 2,064 (2.80) | 40,471 | 13,620 (7.00) | 39,134 | 4,227 (2.32) |
| 70–79 | 29,009 | 4,396 (2.27) | 15,715 | 1,860 (2.52) | 31,186 | 6,748 (3.47) | 30,114 | 3,419 (1.88) |
| 80+ | 16,754 | 2,283 (1.18) | 10,100 | 1,186 (1.61) | 18,702 | 3,087 (1.59) | 17,429 | 2046 (1.12) |
| Most D Q-1 | 38,885 | 4,495 (2.32) | 17,024 | 2,429 (3.29) | 39,347 | 10,631 (5.46) | 36,625 | 5,520 (3.03) |
| Q-2 | 41,545 | 3,757 (1.94) | 16,680 | 1,875 (2.54) | 41,937 | 12,015 (6.17) | 39,050 | 4,901 (2.69) |
| Q-3 | 39,828 | 3,386 (1.75) | 15,376 | 1,585 (2.15) | 40,401 | 12,045 (6.19) | 37,794 | 4,201 (2.31) |
| Q-4 | 37,137 | 2,594 (1.34) | 13,101 | 1,138 (1.54) | 36,865 | 11,163 (5.74) | 34,566 | 3,581 (1.97) |
| Least D Q-5 | 36,101 | 2027 (1.05) | 11,625 | 893 (1.21) | 36,074 | 11,652 (5.99) | 34,027 | 3,035 (1.67) |
FBSL Fasting Blood Sugar Level, HbA1c Glycated Haemoglobin, TC Total Cholesterol, HDL High Density Lipoprotein, Most D Most Disadvantaged, Least D Least Disadvantaged
*Refer to Table 1 for high risk threshold levels of CMRFs.
Cross-tabulation of individual CMRFs (ACR, eGFR, and Obesity) with the variables in study.
| CMRFs | ACR | eGFR | Obesity | |||
|---|---|---|---|---|---|---|
| Total tests | Higher risk* results, n (%) | Total tests | Higher risk* results, n (%) | Total tests | Higher risk* results, n (%) | |
| Rates | 50,737 | 2046 (4.03) | 243,908 | 27,205 (11.15) | 192,261 | 64,875 (33.7) |
| Male | 25,043 | 1,265 (2.49) | 108,140 | 12,441 (5.1) | 86,853 | 29,585 (15.3) |
| Female | 25,694 | 781 (1.54) | 135,768 | 14,764 (6.05) | 105,408 | 35,290 (18.3) |
| 18–29 | 1546 | 47 (0.09) | 32,961 | 72 (0.03) | 23,277 | 4,582 (2.38) |
| 30–39 | 2,278 | 71 (0.14) | 29,047 | 105 (0.04) | 22,799 | 6,535 (3.40) |
| 40–49 | 4,870 | 108 (0.21) | 35,778 | 330 (0.14) | 30,401 | 10,595 (5.51) |
| 50–59 | 9,272 | 230 (0.45) | 42,695 | 1,112 (0.46) | 37,285 | 13,825 (7.19) |
| 60–69 | 13,388 | 412 (0.81) | 43,423 | 3,626 (1.49) | 38,370 | 15,310 (7.96) |
| 70–79 | 12,337 | 605 (1.19) | 34,406 | 8,507 (3.49) | 30,074 | 11,324 (5.89) |
| 80+ | 7,046 | 573 (1.13) | 25,598 | 13,453 (5.52) | 10,055 | 2,704 (1.41) |
| Most D Q-1 | 11,915 | 638 (1.26) | 49,288 | 7,061 (2.89) | 37,476 | 15,365 (7.99) |
| Q-2 | 11,350 | 485 (0.96) | 52,947 | 6,354 (2.61) | 40,172 | 14,334 (7.46) |
| Q-3 | 10,494 | 391 (0.77) | 50,816 | 5,917 (2.43) | 39,133 | 13,007 (6.77) |
| Q-4 | 8,732 | 308 (0.61) | 46,440 | 4,406 (1.81) | 37,370 | 11,766 (6.12) |
| Least D Q-5 | 8,246 | 224 (0.44) | 44,417 | 3,467 (1.42) | 38,110 | 10,403 (5.41) |
ACR Albumin Creatinine Ratio, eGFR estimated Glomerular Filtration Rate, BMI Body Mass Index, Most D Most Disadvantaged, Least D Least Disadvantaged.
*Refer to Table 1 for higher risk threshold levels of CMRFs.
Summary model fit values and comparison of the multilevel models.
| FBSL | HbA1c | TC | HDL | ACR | eGFR | Obesity | |
|---|---|---|---|---|---|---|---|
| AIC | 103,645 | 49,897 | 227,464 | 123,277 | 16,596 | 115,340 | 242,064 |
| AUC | 0.70 | 0.56 | 0.63 | 0.67 | 0.65 | 0.88 | 0.56 |
| AIC | 111,022.8 | 50,114.5 | 235,931.6 | 130,649.7 | 17,130.0 | 167,164.8 | 242,793.2 |
| 0.101 | 0.103 | 0.026 | 0.071 | 0.092 | 0.189 | 0.115 | |
| ICC (%) | 3.0 | 3.0 | 0.8 | 2.1 | 2.7 | 5.4 | 3.4 |
| MOR | 1.35 | 1.36 | 1.16 | 1.29 | 1.34 | 1.51 | 1.38 |
| AUC | 0.61 | 0.63 | 0.56 | 0.60 | 0.70 | 0.64 | 0.60 |
| AIC | 103,066.2 | 49,690.2 | 227,254.6 | 122,700.0 | 16,585.2 | 115,257.1 | 239,122.6 |
| 0.103 | 0.106 | 0.020 | 0.081 | 0.073 | 0.024 | 0.117 | |
| ICC (%) | 3.0 | 3.1 | 0.6 | 2.4 | 2.2 | 0.7 | 3.4 |
| MOR | 1.36 | 1.36 | 1.14 | 1.31 | 1.30 | 1.16 | 1.39 |
| AUC | 0.73 | 0.64 | 0.64 | 0.71 | 0.69 | 0.89 | 0.63 |
| AUC change† | + 0.03 | + 0.08 | + 0.01 | + 0.04 | + 0.04 | + 0.01 | + 0.07 |
| PCV | + 1.88% | + 3.02% | − 21.76% | + 15.25% | − 20.53% | − 87.26% | + 1.48% |
| AIC | 110,552.5 | 49,875.3 | 235,795.4 | 130,294.3 | 17,053.0 | 166,930.0 | 242,443.7 |
| 0.034 | 0.047 | 0.018 | 0.030 | 0.044 | 0.138 | 0.071 | |
| ICC (%) | 1.0 | 1.4 | 0.6 | 0.9 | 1.3 | 4.0 | 2.1 |
| MOR | 1.19 | 1.23 | 1.14 | 1.18 | 1.22 | 1.43 | 1.29 |
| AUC | 0.60 | 0.61 | 0.56 | 0.59 | 0.62 | 0.63 | 0.60 |
| PCV | − 66.41% | − 54.82% | − 27.81% | − 58.05% | − 52.88% | − 26.84% | − 38.76% |
| AIC | 102,689.6 | 49,453.3 | 227,199.2 | 122,328.3 | 16,527.2 | 115,125.7 | 238,748.4 |
| 0.044 | 0.049 | 0.017 | 0.034 | 0.036 | 0.014 | 0.069 | |
| ICC (%) | 1.3 | 1.5 | 0.5 | 1.0 | 1.1 | 0.4 | 2.0 |
| MOR | 1.22 | 1.24 | 1.13 | 1.19 | 1.20 | 1.12 | 1.28 |
| AUC | 0.72 | 0.63 | 0.64 | 0.70 | 0.67 | 0.88 | 0.62 |
| PCV | − 56.33% | − 51.91% | − 33.27% | − 51.37% | − 61.19% | − 92.79% | − 40.30% |
†Change in relation to M0; τ2—Variance; AIC—Akaike Information Criterion; AUC—Area under the receiver operating characteristic curve; ICC—Intra-cluster Correlation Coefficients; MOR—Median Odds Ratios; PCV—proportional change in variance (in relation to Model 1 s).
Figure 2ROC curves of the fitted models (Model 3s and Model 4s) of CMRFs for comparison: (a) FBSL models; (b) HbA1c models; (c) TC models; (d) HDL models; (e) ACR models; (f) FBSL models; (g) obesity models; Model 3s—CMRFs adjusted only for IRSD quintiles of areas; Model 4s—Final models of CMRFs adjusted for age + sex + IRSD quintiles of area.
Single and multilevel logistic regression model summaries for high FBSL (FBSL ≥ 7.0 mmol/L).
| Single level model | Multilevel models | ||||
|---|---|---|---|---|---|
| Model 0 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Significance (LRT) | *** | *** | *** | *** | *** |
| High FBSL | OR (95% CI) | OR (95% CI) | OR (95% CI)OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Intercept | 0.01 (0.01–0.01) | 0.09 (0.09–0.09) | 0.01 (0.01–0.01) | 0.06 (0.06–0.06) | 0.01 (0.01–0.01) |
| Female | Reference | – | |||
| Male | 1.62 (1.56–1.67) | 1.63 (1.56–1.7) | 1.63 (1.58–1.7) | ||
| 18–29 | Reference | – | 1.64 (1.41–1.9) | ||
| 30–39 | 1.60 (1.36–1.87) | 1.63 (1.39–1.9) | 3.58 (3.12–4.1) | ||
| 40–49 | 3.41 (2.97–3.93) | 3.53 (3.07–4.1) | 6.81 (5.98–7.8) | ||
| 50–59 | 6.48 (5.68–7.42) | 6.77 (5.93–7.7) | 11.05 (9.71–12.6) | ||
| 60–69 | 10.48 (9.21–11.98) | 11.07 (9.72–12.6) | 13.74 (12.07–15.6) | ||
| 70–79 | 13.35 (11.73–15.27) | 13.93 (12.22–15.9) | 12.02 (10.52–13.7) | ||
| 80+ | 12.01 (10.51–13.78) | 12.33 (10.79–14.1) | |||
| Q-5 | Reference | – | |||
| Q-4 | 1.27 (1.18–1.36) | 1.27 (1.18–1.37) | |||
| Q-3 | 1.58 (1.47–1.69) | 1.49 (1.39–1.61) | |||
| Q-2 | 1.68 (1.57–1.80) | 1.62 (1.50–1.74) | |||
| Most D Q-1 | 2.20 (2.06–2.36) | 2.11 (1.96–2.26) | |||
| 103,645 | 111,022.8 | 103,066.2 | 110,552.5 | 102,689.6 | |
| 0.101 | 0.103 | 0.034 | 0.044 | ||
| – | + 1.88% | − 66.41% | − 56.33% | ||
| 3.00 | 3.00 | 1.0 | 1.3 | ||
| 1.35 | 1.36 | 1.19 | 1.22 | ||
| 0.70 | 0.61 | 0.73 | 0.60 | 0.72 | |
| + 0.03 | |||||
| Proportional variance explained by IRSD: 57.14% | |||||
***p < 0.001; †Change in Model 2 in relation to Model 0; Model 0—Single level model adjusted for age + sex; Model 1—null model at SA1 level; Model 2—M1 + individual-level: age + sex; Model 3—Model 1 + Area level: IRSD quintiles of SA1s; Model 4—Model 1 + Model 2 + Model 3.
Single and multilevel logistic regression model summaries for high HbA1c (HbA1c > 7.5%).
| Single level model | Multilevel models | ||||
|---|---|---|---|---|---|
| Model 0 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Significance (LRT) | *** | *** | *** | *** | *** |
| High HbA1c | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Intercept | 0.07 (0.06–0.08) | 0.12 (0.12–0.12) | 0.07 (0.06–0.07) | 0.08 (0.08–0.09) | 0.05 (0.04–0.05) |
| Female | Reference | – | – | ||
| Male | 1.37 (1.31–1.43) | 1.38 (1.32–1.45) | 1.39 (1.32–1.45) | ||
| 18–29 | Reference | – | – | ||
| 30–39 | 0.81 (0.68–0.96) | 0.81 (0.68–0.96) | 0.81 (0.68–0.96) | ||
| 40–49 | 1.22 (1.06–1.42) | 1.24 (1.07–1.44) | 1.26 (1.08–1.46) | ||
| 50–59 | 1.53 (1.34–1.77) | 1.56 (1.36–1.80) | 1.57 (1.36–1.81) | ||
| 60–69 | 1.61 (1.40–1.85) | 1.64 (1.43–1.88) | 1.64 (1.43–1.88) | ||
| 70–79 | 1.63 (1.42–1.87) | 1.64 (1.42–1.88) | 1.62 (1.41–1.86) | ||
| 80 + | 1.64 (1.43–1.90) | 1.63 (1.41–1.88) | 1.60 (1.39–1.85) | ||
| Q-5 | Reference | – | |||
| Q-4 | 0.08 (0.08–0.09) | 1.15 (1.04–1.28) | |||
| Q-3 | 1.14 (1.03–1.27) | 1.39 (1.26–1.54) | |||
| Q-2 | 1.40 (1.27–1.54) | 1.55 (1.41–1.71) | |||
| Most D Q-1 | 1.54 (1.40–1.69) | 2.02 (1.84–2.22) | |||
| 49,897 | 50,114.5 | 49,690.2 | 49,875.3 | 49,453.3 | |
| 0.103 | 0.106 | 0.047 | 0.049 | ||
| – | + 3.02% | − 54.82% | − 51.91% | ||
| 3.0 | 3.1 | 1.4 | 1.5 | ||
| 1.36 | 1.36 | 1.23 | 1.24 | ||
| 0.56 | 0.63 | 0.64 | 0.61 | 0.63 | |
| + 0.08 | |||||
| Proportional variance explained by IRSD: 53.31% | |||||
***p < 0.001; †Change in Model 2 in relation to Model 0; Model 0—Single level model adjusted for age + sex; Model 1—null model at SA1 level; Model 2—Model 1 + individual-level: age + sex; Model 3—Model 1 + Area level: IRSD quintiles of SA1s; Model 4—Model 1 + Model 2 + Model 3.
Single and multilevel logistic regression model summaries for high TC (TC ≥ 5.5 mmol/L).
| Single level model | Multilevel models | ||||
|---|---|---|---|---|---|
| Model 0 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Significance (LRT) | *** | *** | *** | *** | *** |
| High TC | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Intercept | 0.20 (0.19–0.21) | 0.42 (0.42–0.42) | 0.20 (0.19–0.21) | 0.08 (0.08–0.09) | 0.22 (0.21–0.23) |
| Female | Reference | – | – | ||
| Male | 0.69 (0.68–0.71) | 0.69 (0.68–0.71) | 0.69 (0.68–0.71) | ||
| 18–29 | Reference | – | – | ||
| 30–39 | 2.01 (1.90–2.13) | 2.02 (1.91–2.14) | 2.01 (1.90–2.13) | ||
| 40–49 | 3.01 (2.86–3.17) | 3.01 (2.86–3.17) | 3.00 (2.85–3.16) | ||
| 50–59 | 4.09 (3.89–4.30) | 4.08 (3.88–4.29) | 4.07 (3.87–4.28) | ||
| 60–69 | 2.97 (2.83–3.13) | 2.95 (2.80–3.10) | 2.95 (2.80–3.10) | ||
| 70–79 | 1.61 (1.53–1.70) | 1.60 (1.52–1.69) | 1.61 (1.52–1.70) | ||
| 80 + | 1.14 (1.07–1.21) | 1.13 (1.07–1.20) | 1.14 (1.07–1.21) | ||
| Q-5 | Reference | – | |||
| Q-4 | 0.91 (0.87–0.95) | 0.94 (0.90–0.98) | |||
| Q-3 | 0.88 (0.85–0.92) | 0.94 (0.90–0.98) | |||
| Q-2 | 0.84 (0.80–0.87) | 0.90 (0.87–0.94) | |||
| Most D Q-1 | 0.77 (0.74–0.81) | 0.84 (0.81–0.88) | |||
| 227,464 | 235,931.6 | 227,254.6 | 235,795.4 | 227,199.2 | |
| 0.026 | 0.020 | 0.018 | 0.017 | ||
| - | − 21.76% | − 27.81% | − 33.27% | ||
| 0.8 | 0.6 | 0.6 | 0.5 | ||
| 1.16 | 1.14 | 1.14 | 1.13 | ||
| 0.63 | 0.56 | 0.64 | 0.56 | 0.64 | |
| + 0.01 | |||||
| Proportional variance explained by IRSD: 14.71% | |||||
***p < 0.001; †Change in Model 2 in relation to Model 0; Model 0—Single level model adjusted for age + sex; Model 1—null model at SA1 level; Model 2—M1 + individual-level: age + sex; Model 3—Model 1 + Area level: IRSD quintiles of SA1s; Model 4—Model 1 + Model 2 + Model 3.
Single and multilevel logistic regression model summaries for low HDL (HDL < 1 mmol/L).
| Single level model | Multilevel models | ||||
|---|---|---|---|---|---|
| Model 0 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Significance (LRT) | *** | *** | *** | *** | *** |
| Low HDL | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Intercept | 0.06 (0.06–0.07) | 0.13 (0.13–0.13) | 0.06 (0.06–0.07) | 0.10 (0.09–0.10) | 0.05 (0.04–0.05) |
| Female | Reference | – | – | ||
| Male | 3.92 (3.80–4.05) | 3.98 (3.85–4.11) | 3.98 (3.85–4.11) | ||
| 18–29 | Reference | – | – | ||
| 30–39 | 1.11 (1.03–1.20) | 1.11 (1.03–1.20) | 1.12 (1.04–1.21) | ||
| 40–49 | 0.97 (0.91–1.04) | 0.99 (0.92–1.05) | 1.00 (0.93–1.07) | ||
| 50–59 | 0.87 (0.81–0.93) | 0.88 (0.82–0.94) | 0.89 (0.83–0.95) | ||
| 60–69 | 0.81 (0.76–0.87) | 0.82 (0.77–0.88) | 0.82 (0.77–0.88) | ||
| 70–79 | 0.85 (0.80–0.91) | 0.86 (0.80–0.92) | 0.85 (0.79–0.91) | ||
| 80+ | 0.94 (0.87–1.01) | 0.93 (0.86–1.00) | 0.91 (0.85–0.98) | ||
| Q-5 | Reference | – | |||
| Q-4 | 1.18 (1.11–1.26) | 1.20 (1.13–1.28) | |||
| Q-3 | 1.29 (1.21–1.37) | 1.32 (1.24–1.41) | |||
| Q-2 | 1.48 (1.39–1.57) | 1.51 (1.42–1.61) | |||
| Most D Q-1 | 1.81 (1.71–1.92) | 1.90 (1.78–2.02) | |||
| 123,277 | 130,649.7 | 122,700.0 | 130,294.3 | 122,328.3 | |
| 0.071 | 0.081 | 0.030 | 0.034 | ||
| – | +15.25% | −58.05% | −51.37% | ||
| 2.1 | 2.4 | 0.9 | 1.0 | ||
| 1.29 | 1.31 | 1.18 | 1.19 | ||
| 0.67 | 0.60 | 0.71 | 0.59 | 0.70 | |
| + 0.04 | |||||
| Proportional variance explained by IRSD: 57.8% | |||||
***p < 0.001; †Change in Model 2 in relation to Model 0; Model 0—Single level model adjusted for age + sex; Model 1—null model at SA1 level; Model 2—M1 + individual-level: age + sex; Model 3—Model 1 + Area level: IRSD quintiles of SA1s; Model 4—Model 1 + Model 2 + Model 3.
Single and multilevel logistic regression model summaries for high ACR (ACR ≥ 30 mcg/L to mg/L).
| Single level model | Multilevel models | ||||
|---|---|---|---|---|---|
| Model 0 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Significance (LRT) | *** | *** | *** | *** | *** |
| High ACR | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Intercept | 0.02 (0.02–0.03) | 0.04 (0.04–0.04) | 0.02 (0.02–0.03) | 0.03 (0.02–0.03) | 0.02 (0.01–0.02) |
| Female | Reference | – | – | – | |
| Male | 1.74 (1.59–1.91) | 1.75 (1.59–1.92) | 1.76 (1.60–1.93) | ||
| 18–29 | Reference | – | – | ||
| 30–39 | 0.99 (0.69–1.45) | 1.00 (0.69–1.45) | 0.99 (0.68–1.44) | ||
| 40–49 | 0.68 (0.49–0.98) | 0.69 (0.49–0.97) | 0.70 (0.49–0.98) | ||
| 50–59 | 0.76 (0.56–1.06) | 0.77 (0.56–1.05) | 0.77 (0.56–1.05) | ||
| 60–69 | 0.95 (0.70–1.30) | 0.95 (0.70–1.30) | 0.95 (0.70–1.29) | ||
| 70–79 | 1.54 (1.15–2.11) | 1.55 (1.14–2.09) | 1.52 (1.12–2.05) | ||
| 80+ | 2.73 (2.04–3.74) | 2.74 (2.02–3.71) | 2.65 (1.96–3.59) | ||
| Q-5 | Reference | – | |||
| Q-4 | 1.31 (1.10–1.57) | 1.25 (1.04–1.50) | |||
| Q-3 | 1.39 (1.16–1.65) | 1.27 (1.06–1.51) | |||
| Q-2 | 1.61 (1.36–1.90) | 1.45 (1.23–1.72) | |||
| Most D Q-1 | 2.02 (1.72–2.38) | 1.84 (1.56–2.16) | |||
| 16,596 | 17,130.0 | 16,585.2 | 17,053.0 | 16,527.2 | |
| 0.092 | 0.073 | 0.044 | 0.036 | ||
| – | − 20.53% | − 52.88% | − 61.19% | ||
| 2.7 | 2.2 | 1.3 | 1.1 | ||
| 1.34 | 1.30 | 1.22 | 1.20 | ||
| 0.65 | 0.70 | 0.69 | 0.62 | 0.67 | |
| + 0.04 | |||||
| Proportional variance explained by IRSD: 51.17% | |||||
***p < 0.001; †Change in Model 2 in relation to Model 0; Model 0—Single level model adjusted for age + sex; Model 1—null model at SA1 level; Model 2—M1 + individual-level: age + sex; Model 3—Model 1 + Area level: IRSD quintiles of SA1s; Model 4—Model 1 + Model 2 + Model 3.
Single and multilevel logistic regression model summaries for low eGFR (eGFR < 60 mL/min/1.73 m2).
| Single level model | Multilevel models | ||||
|---|---|---|---|---|---|
| Model 0 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Significance (LRT) | *** | *** | *** | *** | *** |
| Low eGFR | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Intercept | 0.00 (0.00–0.00) | 0.13 (0.12–0.13) | 0.00 (0.00–0.00) | 0.08 (0.07–0.08) | 0.00 (0.00–0.00) |
| Female | Reference | – | – | ||
| Male | 0.98 (0.95–1.01) | 0.98 (0.95–1.01) | 0.98 (0.95–1.01) | ||
| 18–29 | Reference | – | – | ||
| 30–39 | 1.66 (1.23–2.25) | 1.66 (1.24–2.20) | 1.66 (1.24–2.22) | ||
| 40–49 | 4.26 (3.32–5.54) | 4.26 (3.34–5.42) | 4.30 (3.36–5.49) | ||
| 50–59 | 12.24 (9.72–15.68) | 12.26 (9.78–15.35) | 12.32 (9.80–15.47) | ||
| 60–69 | 41.72 (33.30–53.19) | 41.81 (33.55–52.1) | 41.86 (33.49–52.31) | ||
| 70–79 | 150.44 (120.24–191.57) | 150.66 (121–187.6) | 149.53 (120–186.6) | ||
| 80+ | 506.80 (405.05–645.35) | 509.18 (409–633.9) | 501.47 (401.7–626) | ||
| Q-5 | Reference | – | |||
| Q-4 | 1.23 (1.12–1.35) | 1.09 (1.03–1.16) | |||
| Q-3 | 1.59 (1.45–1.74) | 1.19 (1.13–1.26) | |||
| Q-2 | 1.65 (1.51–1.81) | 1.22 (1.15–1.29) | |||
| Most D Q-1 | 1.97 (1.80–2.15) | 1.38 (1.31–1.46) | |||
| 115,340 | 167,164.8 | 115,257.1 | 166,930.0 | 115,125.7 | |
| 0.189 | 0.024 | 0.138 | 0.014 | ||
| – | − 87.26% | − 26.84% | − 92.79% | ||
| 5.4 | 0.7 | 4.0 | 0.4 | ||
| 1.51 | 1.16 | 1.43 | 1.12 | ||
| 0.88 | 0.64 | 0.89 | 0.63 | 0.88 | |
| + 0.01 | |||||
| Proportional variance explained by IRSD: 41.75% | |||||
***p < 0.001; †Change in Model 2 in relation to Model 0; Model 0—Single level model adjusted for age + sex; Model 1—null model at SA1 level; Model 2—M1 + individual-level: age + sex; Model 3—Model 1 + Area level: IRSD quintiles of SA1s; Model 4—Model 1 + Model 2 + Model 3.
Single and multilevel logistic regression model summaries for obesity (BMI ≥ 30 kg/m2).
| Single level model | Multilevel models | ||||
|---|---|---|---|---|---|
| Model 0 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Significance (LRT) | *** | *** | *** | *** | *** |
| Obesity | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Intercept | 0.25 (0.24–0.25) | 0.51 (0.50–0.51) | 0.25 (0.24–0.26) | 0.37 (0.35–0.39) | 0.18 (0.17–0.19) |
| Female | Reference | – | – | ||
| Male | 0.99 (0.97–1.00) | 0.99 (0.97–1.01) | 0.99 (0.97–1.01) | ||
| 18–29 | Reference | – | – | ||
| 30–39 | 1.64 (1.57–1.71) | 1.63 (1.56–1.71) | 1.64 (1.57–1.71) | ||
| 40–49 | 2.18 (2.10–2.27) | 2.20 (2.11–2.29) | 2.21 (2.12–2.30) | ||
| 50–59 | 2.41 (2.32–2.50) | 2.44 (2.34–2.53) | 2.44 (2.35–2.54) | ||
| 60–69 | 2.71 (2.61–2.82) | 2.73 (2.63–2.84) | 2.74 (2.63–2.84) | ||
| 70–79 | 2.47 (2.37–2.57) | 2.44 (2.34–2.54) | 2.43 (2.33–2.53) | ||
| 80+ | 1.50 (1.42–1.59) | 1.46 (1.38–1.55) | 1.45 (1.37–1.53) | ||
| Q-5 | Reference | - | |||
| Q-4 | 1.25 (1.17–1.33) | 1.26 (1.18–1.34) | |||
| Q-3 | 1.37 (1.29–1.46) | 1.38 (1.30–1.47) | |||
| Q-2 | 1.51 (1.42–1.61) | 1.54 (1.44–1.64) | |||
| Most D Q-1 | 1.90 (1.79–2.03) | 1.94 (1.83–2.07) | |||
| 242,064 | 242,793.2 | 239,122.6 | 242,443.7 | 238,748.4 | |
| 0.115 | 0.117 | 0.071 | 0.069 | ||
| – | + 1.48% | − 38.76% | − 40.30% | ||
| 3.4 | 3.4 | 2.1 | 2.0 | ||
| 1.38 | 1.39 | 1.29 | 1.28 | ||
| 0.56 | 0.60 | 0.63 | 0.60 | 0.62 | |
| + 0.07 | |||||
| Proportional variance explained by IRSD: 41.06% | |||||
***p < 0.001; †Change in Model 2 in relation to Model 0; Model 0—Single level model adjusted for age + sex; Model 1—Single level model adjusted for age + sex; Model 1—null model at SA1 level; Model 2—M1 + individual-level: age + sex; Model 3—Model 1 + Area level: IRSD quintiles of SA1s; Model 4—Model 1 + Model 2 + Model 3.